Stocksigma LogoStocksigma Logo

Bharat Parenterals Subsidiary Innoxel Receives USFDA EIR for Vadodara Injectables Facility

Bharat Parenterals' subsidiary, Innoxel Lifesciences, received an Establishment Inspection Report (EIR) from the USFDA on 4th Nov'26, successfully closing

Bharat Parenterals Subsidiary Innoxel Receives USFDA EIR for Vadodara Injectables Facility

Bharat Parenterals Ltd 路 Press Release 路 05 Nov 2026, 8:10 pm

Bharat Parenterals Subsidiary Innoxel Receives USFDA EIR for Vadodara Injectables Facility Bharat Parenterals' subsidiary, Innoxel Lifesciences, received an Establishment Inspection Report (EIR) from the USFDA on 4th Nov'26, successfully closing an unannounced Pre-Approval Inspection conducted between 13th Apr'26 and 20th Apr'26 at its Vadodara finished dosage facility. The USFDA confirmed the plant is ready for commercial operations of a general injectable product with no further questions. This marks the site's second USFDA EIR alongside an existing EU-GMP certification, strengthening its regulated-market CDMO capabilities following its first US commercial launch in Oct'26.

Original exchange filing (PDF)

More announcements from Bharat Parenterals Ltd

All Bharat Parenterals Ltd announcements